NCT05122182

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

An Investigator Initiated, International Multi-Centre, Multi-Arm, Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: University of Sydney · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

CLARITY 2.0 is an investigator-initiated trial that will evaluate the safety and efficacy of dual treatment with repagermanium, a CCR2 antagonist, and candesartan, an ARB, in patients hospitalised with COVID-19 disease.

Conditions

• COVID-19
• SARS-CoV2 Infection

Interventions

Type	Name	Description
DRUG	Candesartan Cilexetil	Angiotensin Receptor Blocker (ARB)
DRUG	Repagermanium	C-C chemokine receptor type 2 (CCR2) antagonist
DRUG	Candesartan Placebo	Angiotensin Receptor Blocker (ARB) placebo
DRUG	Repagermanium Placebo	C-C chemokine receptor type 2 (CCR2) antagonist placebo

Timeline

• Start date: 2022-01-07
• Primary completion: 2022-08-15
• Completion: 2023-01-28
• First posted: 2021-11-16
• Last updated: 2023-09-15

Locations

10 sites across 1 country: India